These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 28368960)
21. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273 [TBL] [Abstract][Full Text] [Related]
22. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717 [TBL] [Abstract][Full Text] [Related]
23. [Vaccines for the treatment of non-small cell lung cancer]. Leduc C; Quoix E Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445 [TBL] [Abstract][Full Text] [Related]
24. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582 [TBL] [Abstract][Full Text] [Related]
25. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
26. Phase I Trial of Intratumoral Injection of Lee JM; Lee MH; Garon E; Goldman JW; Salehi-Rad R; Baratelli FE; Schaue D; Wang G; Rosen F; Yanagawa J; Walser TC; Lin Y; Park SJ; Adams S; Marincola FM; Tumeh PC; Abtin F; Suh R; Reckamp KL; Lee G; Wallace WD; Lee S; Zeng G; Elashoff DA; Sharma S; Dubinett SM Clin Cancer Res; 2017 Aug; 23(16):4556-4568. PubMed ID: 28468947 [No Abstract] [Full Text] [Related]
27. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472 [TBL] [Abstract][Full Text] [Related]
28. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients. Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871 [TBL] [Abstract][Full Text] [Related]
30. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Abdel-Wahab Z; DeMatos P; Hester D; Dong XD; Seigler HF Cell Immunol; 1998 May; 186(1):63-74. PubMed ID: 9637766 [TBL] [Abstract][Full Text] [Related]
31. DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. Leaf RK; Stroopinsky D; Pyzer AR; Kruisbeek AM; van Wetering S; Washington A; Ephraim A; Cole L; Morin A; Jain S; Nahas MR; Apel A; Arnason J; Hamdan A; Rosenblatt J; Avigan D J Immunother; 2017; 40(9):315-322. PubMed ID: 28961609 [TBL] [Abstract][Full Text] [Related]
32. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL. Wolfraim LA; Takahara M; Viley AM; Shivakumar R; Nieda M; Maekawa R; Liu LN; Peshwa MV Int Immunopharmacol; 2013 Mar; 15(3):488-97. PubMed ID: 23474736 [TBL] [Abstract][Full Text] [Related]
33. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054 [TBL] [Abstract][Full Text] [Related]
34. TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles). Xing Y; Cao R; Hu HM Cell Death Dis; 2016 Aug; 7(8):e2322. PubMed ID: 27490927 [TBL] [Abstract][Full Text] [Related]
35. Fusion of the Human Cytomegalovirus pp65 antigen with both ubiquitin and ornithine decarboxylase additively enhances antigen presentation to CD8(+) T cells in human dendritic cells. Park MJ; Kim EK; Han JY; Cho HW; Sohn HJ; Kim SY; Kim TG Hum Gene Ther; 2010 Aug; 21(8):957-67. PubMed ID: 20218861 [TBL] [Abstract][Full Text] [Related]
36. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240 [TBL] [Abstract][Full Text] [Related]
37. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses. Zhou Y; McEarchern JA; Howard E; Pestano G; Salgaller ML; Bosch ML Cancer Immunol Immunother; 2003 Jul; 52(7):413-22. PubMed ID: 12835918 [TBL] [Abstract][Full Text] [Related]
38. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody. Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333 [TBL] [Abstract][Full Text] [Related]